Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). - Leonardi,C.; Kimball,A.B.; Papp,K. (Lancet, 2008)